このエントリーをはてなブックマークに追加


ID 65154
JaLCDOI
FullText URL
77_2_221.pdf 3.24 MB
Author
Iriyoshi, Hiroki Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Sada, Ken-ei Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Miyauchi, Atsushi Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Yamamoto, Hirotaka Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Hashimoto, Daisuke Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Nojima, Shigeru Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Yamanaka, Shingo Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Kawamura, Masafumi Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Oka, Satoshi Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital
Abstract
Several previous case reports have shown that patients with immunoglobulin D (IgD) multiple myeloma (MM) can be withdrawn from hemodialysis, however, the characteristics that can predict withdrawal in these patients have not yet been elucidated. A 57-year-old Japanese woman required hemodialysis because of renal dysfunction due to IgD-λ and Bence Jones protein-λ MM. Bortezomib-based chemotherapy nine days after admission led to her withdrawal from hemodialysis on Day 50. In our case-based review, younger age and early initiation of bortezomib-based chemotherapy emerged as possible predictors of successful hemodialysis withdrawal.
Keywords
IgD-type multiple myeloma
acute renal dysfunction
urinary protein
hemodialysis
bortezomib
Amo Type
Case Report
Publication Title
Acta Medica Okayama
Published Date
2023-04
Volume
volume77
Issue
issue2
Publisher
Okayama University Medical School
Start Page
221
End Page
225
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
English
Copyright Holders
Copyright Ⓒ 2023 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT